MétaCan
Menu
Back to cohort
Record W2047207959 · doi:10.1177/0884533608329707

Comment On: Omega‐3 Free Fatty Acids for the Maintenance of Remission in Crohn Disease: The EPIC Randomized Controlled Trials

2009· article· en· W2047207959 on OpenAlex
Alex Ulitsky

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

aboutThe title or abstract carries a Canadian signal from the geographic lexicon.
no affNo Canadian affiliation: this work is invisible to an affiliation-only frame.
No Canadian affiliation. An affiliation-only frame, the usual design, would never have seen this work. It is one of the works that make the case for inverting the frame.

Bibliographic record

VenueNutrition in Clinical Practice · 2009
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsnot available
Fundersnot available
KeywordsMedicinePlaceboCrohn's diseaseInternal medicineContext (archaeology)Randomized controlled trialGastroenterologyDiseaseClinical endpointEPICClinical trialPathology

Abstract

fetched live from OpenAlex

Context: Maintenance therapy for Crohn disease features the use of immunosuppressive drugs, which are associated with an increased risk of infection. Identification of safe and effective maintenance strategies is a priority. Objective: To determine whether the oral administration of omega‐3 free fatty acids is more effective than placebo for prevention of relapse of Crohn disease. Design, Setting, and Patients: Two randomized, double‐blind, placebo‐controlled studies (Epanova Program in Crohn's Study 1 [EPIC‐1] and EPIC‐2) conducted between January 2003 and February 2007 at 98 centers in Canada, Europe, Israel, and the United States. Data from 363 and 375 patients with quiescent Crohn disease were evaluated in EPIC‐1 and EPIC‐2, respectively. Interventions: Patients with a Crohn's Disease Activity Index (CDAI) score of less than 150 were randomly assigned to receive either 4 g/d of omega‐3 free fatty acids or placebo for up to 58 weeks. No other treatments for Crohn disease were permitted. Main Outcome Measure: Clinical relapse, as defined by a CDAI score of 150 points or greater and an increase of more than 70 points from the baseline value, or initiation of treatment for active Crohn disease. Results: For EPIC‐1, 188 patients were assigned to receive omega‐3 free fatty acids and 186 patients to receive placebo. Corresponding numbers for EPIC‐2 were 189 and 190 patients, respectively. The rate of relapse at 1 year in EPIC‐1 was 31.6% in patients who received omega‐3 free fatty acids and 35.7% in those who received placebo (hazard ratio, 0.82; 95% confidence interval, 0.51‐1.19; P = .30). Corresponding values for EPIC‐2 were 47.8% and 48.8% (hazard ratio, 0.90; 95% confidence interval, 0.67‐1.21; P = .48). Serious adverse events were uncommon and mostly related to Crohn disease. Conclusion: In these trials, treatment with omega‐3 free fatty acids was not effective for the prevention of relapse in Crohn disease. (JAMA. 2008;299:1690‐1697.) Feagan BG, Sandborn WJ, Mittmann U, et al.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.022
metaresearch head score (Gemma)0.187
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.750
Threshold uncertainty score0.820

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0220.187
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.048
GPT teacher head0.402
Teacher spread0.354 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it